Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 470,102
  • Shares Outstanding, K 108,820
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,200 K
  • 36-Month Beta 1.15
  • Price/Sales 20.36
  • Price/Cash Flow N/A
  • Price/Book 18.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.06
  • Number of Estimates 4
  • High Estimate -0.04
  • Low Estimate -0.10
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.94 +9.64%
on 10/10/18
5.73 -24.61%
on 10/01/18
-0.53 (-10.93%)
since 09/19/18
3-Month
3.94 +9.64%
on 10/10/18
6.73 -35.81%
on 09/04/18
-0.89 (-17.08%)
since 07/19/18
52-Week
0.97 +345.36%
on 10/31/17
7.21 -40.08%
on 07/09/18
+3.19 (+282.30%)
since 10/19/17

Most Recent Stories

More News
New Research Coverage Highlights TIER REIT, Meridian Bioscience, ArQule, Greenlight Capital Re, ADT, and Turquoise Hill Resources -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TIER REIT, Inc. (NYSE:TIER),...

ADT : 7.77 (+0.26%)
ARQL : 4.32 (-8.09%)
TRQ : 1.81 (-2.69%)
VIVO : 15.57 (+0.06%)
TIER : 22.59 (unch)
GLRE : 12.04 (+2.38%)
ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092)

ArQule, Inc. (Nasdaq:ARQL) today announced the presentation of preliminary clinical data on miransertib (ARQ 092) in three poster presentations at the American Society of Human Genetics (ASHG)...

ARQL : 4.32 (-8.09%)
ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2018 before the market opens on Wednesday, October 31, 2018. The Company will...

ARQL : 4.32 (-8.09%)
ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics (ASHG) 2018 Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting clinical data on the company's lead AKT inhibitor, miransertib (ARQ 092), in three poster presentations at the American...

ARQL : 4.32 (-8.09%)
ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018

ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, and...

ARQL : 4.32 (-8.09%)
ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the...

ARQL : 4.32 (-8.09%)
Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to miransertib (ARQ 092) for the treatment of PIK3CA-Related...

ARQL : 4.32 (-8.09%)
Implied Volatility Surging for ArQule (ARQL) Stock Options

Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.

ARQL : 4.32 (-8.09%)
ArQule to Participate in Citi's 13th Annual Biotech Conference on September 6, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, Peter Lawrence, President and COO, Brian Schwartz, CMO and Head of R&D and Marc Schegerin, Senior Vice President and Head...

ARQL : 4.32 (-8.09%)
ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, and Dr. Brian Schwartz, CMO and Head of Research and Development, will participate in investor meetings and scientific panel...

ARQL : 4.32 (-8.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 5.05
1st Resistance Point 4.69
Last Price 4.32
1st Support Level 4.12
2nd Support Level 3.91

See More

52-Week High 7.21
Fibonacci 61.8% 4.83
Last Price 4.32
Fibonacci 50% 4.09
Fibonacci 38.2% 3.35
52-Week Low 0.97

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar